Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with fellow Chinese firm Zhejiang Anglikang Pharmaceutical Co. Ltd (SHE: 002940) concerning Sun-Novo’s drug candidate, NHKC-1. This development marks a collaborative effort between the two companies to co-develop a treatment for primary hypertension.
NHKC-1: A Drug Candidate for Primary Hypertension
NHKC-1 is currently in development to treat primary hypertension and is the subject of a clinical study designed to assess its bioequivalence, efficacy, and safety. The partnership between Sun-Novo and Anglikang is valued at RMB 150 million (USD 20.7 million), which includes a research and development-linked milestone payment of RMB 75 million. This valuation is contingent upon the drug’s successful progression through development; if a similar product from another manufacturer achieves market approval before NHKC-1, the project value will be adjusted to RMB 100 million, with the milestone payment being adjusted accordingly.
Post-Approval Plans and Roles
Following market approval, Zhejiang Anglikang Pharmaceutical is set to handle the manufacturing and marketing of NHKC-1, while Beijing Sun-Novo Pharmaceutical Research Co., Ltd will assume the role of Marketing Authorization Holder (MAH). This strategic division of responsibilities is aimed at leveraging the strengths of both companies to ensure the successful launch and distribution of NHKC-1 in the market.-Fineline Info & Tech
